Elevated parathyroid hormone levels in older women treated for osteoporosis using denosumab.

Increasing age is associated with iPTH elevations in osteoporotic patients on denosumab. In the absence of any pathology, continuation of denosumab may be safe in lowering fracture risk. However, a larger study may be required to confirm this.